Is PT-141 (Bremelanotide) Legal in Texas?

Print or save as PDF

See the public record for Bremelanotide

  • Approved product / Vyleesi (bremelanotide) 1.75 mg subcutaneous autoinjector, prescription only [1][2]
  • Approval / NDA 210557, June 21, 2019 [2]
  • Approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Not indicated for / Men, postmenopausal women, or enhancing sexual performance [1]
  • Compounded and research PT-141 / Not FDA-approved drugs [3][1]
  • FDA safety-risk bulks list / Bremelanotide not listed [4]

What the federal approval actually covers

Vyleesi is bremelanotide 1.75 mg in a prefilled autoinjector, injected under the skin of the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity [1]. The label says not to administer more than one dose in 24 hours and does not recommend more than eight doses per month [1]. The approved use is narrow: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), meaning low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, or to enhance sexual performance [1].

The Vyleesi label has no boxed warning, and neither the label nor the 2019 approval letter identifies a REMS [1][2].

Is 'PT-141' sold online the same drug as Vyleesi?

No. Vyleesi is the FDA-approved bremelanotide product [3]. Products sold as PT-141, whether as a compounded injection or a vial labeled for research use, are not Vyleesi and are not FDA-approved drugs. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed [3][1].

Where bremelanotide sits in FDA's compounding documents, and what that leaves open for Texas

Bremelanotide is not on FDA's list of bulk drug substances that may present significant safety risks when compounded, a list whose content is dated 04/22/2026 [4], and it appears in no category on FDA's bulk-substance lists [5]. It is also not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6]. None of that is an FDA approval of any compounded bremelanotide product [3].

The prescription-only status above applies to Vyleesi [1][2]. These federal documents do not state whether a particular Texas prescriber or Texas-licensed pharmacy may supply a compounded or research-labeled PT-141 product.

Questions worth asking

Choose the questions you want to keep

What the label says about safety

The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease, and says it is not recommended in patients at high risk for cardiovascular disease [1]. Each dose transiently raises blood pressure: maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down by up to 5 beats per minute [1]. Nausea was reported by 40% of Vyleesi patients in the phase 3 trials versus 1.3% on placebo, and 8% of Vyleesi patients stopped the trials because of it [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, who is the approved use of Vyleesi for?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Do I need a prescription for bremelanotide in the US?
The FDA-approved product, Vyleesi, is prescription only and comes as a 1.75 mg subcutaneous autoinjector [1][2].
What is the difference between Vyleesi and compounded PT-141?
Vyleesi is the FDA-approved bremelanotide product, approved June 21, 2019 under NDA 210557 [2]. Compounded and research-labeled PT-141 products are not FDA-approved drugs and are not reviewed by FDA for safety, effectiveness or quality before marketing [3][1].
Is bremelanotide approved for men or for postmenopausal women?
No. The label states Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance [1].
Is compounded bremelanotide on FDA's safety-risk lists?
Bremelanotide is not on FDA's list of bulk substances that may present significant safety risks when compounded [4], appears in no category on FDA's bulk-substance lists [5], and is not among the six peptides in HHS's October 2026 draft enforcement-discretion policy [6]. Absence from those documents is not an FDA approval of a compounded product [3].
Show all 6 referencesHide references
PT-141 Texas: evidence summary chart
Image: HealthRX.com. Full PT-141 Texas guide and sources at healthrx.com/peptide-legal-pt-141.